+
Site Tour
TRICLIP™
TRICUSPID
VALVE REPAIR
TRANSCATHETER
EDGE-TO-EDGE REPAIR (TEER)

 

Built upon a proven clip-based platform, TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe Tricuspid Regurgitation (TR) who are at high risk for surgery.

A STATE-OF-THE-ART TREATMENT OPTION FOR PATIENTS AT HIGH RISK FOR SURGERY

TriClip™ TEER is a low risk, minimally invasive, non-surgical treatment option for symptomatic patients with severe Tricuspid Regurgitation (TR) who are at high risk for surgery and are not seeing improvement from medical therapy alone.

TriClip™ Patient Story: Cruz

TriClip™ Patient Story: Narcisa

TriClip™ Patient Story: Javier

  • Transcatheter beating heart procedure - no cardiopulmonary bypass
  • Allows for real-time positioning and repositioning to optimize TR reduction
  • Femoral venous access
  • Can be used in a standard catheterization laboratory or hybrid room
  • No pre-procedural CT required
  • Fast recovery times; many patients go home the next day
Patients with severe tricuspid regurgitation have significantly impaired quality of life
  • Shortness of breath
  • Peripheral edema
  • Ascites
  • Fatigue
  • Declining exercise capacity
Current treatment options have limitations

For many patients with Functional Tricuspid Regurgitation (FTR), medical management is not enough.

MEDICAL MANAGEMENT FOR TR HAS LITTLE IMPACT ON SURVIAL6

Surgery is high risk and often denied8-9

Surgery for TR is seldom performed. Factors prohibiting surgery include:

  • High operative risk (6–16% in-hospital mortality)
  • Multiple comorbidities
  • Advanced age
  • Lack of effectiveness

LONG-TERM SURVIVAL ESTIMATES FOR ALL PATIENTS UNDERGOING SURGICAL TRICUSPID VALVE REPLACEMENT OR REPAIR10

    Connext
    Hub

    Learn emerging and established information on cardiovascular conditions and stroke prevention technologies.

    Find out more

     

    TV

    AV VALVES 2023: Fast Forward 20 Years

    AV VALVES Summit 2023 Shaping the Future Part II: Fast Forward 20 Years

    AV VALVES 2023: The Genesis of TEER

    AV VALVES Summit 2023 Shaping the Future Part I: 20 years – The Genesis of TEER

    AV VALVES 2023: TA, TF in TMVR

    AV VALVES Summit 2023 Trending Controversies Round 3: TA, TF in TMVR

    AV VALVES 2023: Replace, Repair in TR

    AV VALVES Summit 2023 Trending Controversies Round 2: Replace, Repair in TR

    AV VALVES 2023: Staged, Concomitant

    AV VALVES Summit 2023 Trending Controversies Round 1: Staged, Concomitant 

    AV VALVES 2023:Decision Making in HF–Tricuspid

    AV VALVES Summit 2023 Decision Making in HF:How & when should I treat? Part II Tricuspid

    AV VALVES 2023:Decision Making in HF – Mitral

    AV VALVES Summit 2023 Decision Making in HF: How & when should I treat? Part I Mitral 

    AV VALVES 2023:HF and VHD – Patient Management

    AV VALVES Summit 2023 HF and VHD: Changing the Paradigm of Patient Management

    AV VALVES 2023: Live Case – T-TEER

    AV VALVES Summit 2023 Live Case: Tricuspid TEER

    AV VALVES 2023: TR – Big Gaps

    AV VALVES Summit 2023 Case Parade Tricuspid: Big Gaps

    References
    1. Data on file at Abbott.
    2. Testing performed by and data on file at Abbott.
    3. von Bardeleben RS, Lurz P, Sitges M, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 2-year outcomes from the TRILUMINATE trial. Presented at EuroPCR 2021.
    4. Lurz P, Schueler R, Goebel B, et al. Real-world outcomes for tricuspid edge-to-edge repair: initial 30-day results from the TriClip™ bRIGHT Study. Presented at PCR London Valves 2021.
    5. Lurz P, von Bardeleben RS, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77(3):229–239. doi.org/10.101 /j.jacc.2020.11.038.
    6. Benfari G, Antoine C, Mille WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. 2019;140(3):196–206. doi.org/10.1161/CIRCULATIONAHA.118.038946.
    7. Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol. 2018;71(25):2935–2956. doi.org/10.1016/j.jacc.2018.04.031.
    8. Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, et al. Tricuspid regurgitation is a public health crisis. Prog Cardiovasc Dis. 2019;62(6):447–451. doi.org/10.1016/j.pcad.2019.10.009.
    9. Wong WK, Chen SW, Chou AH, et al. Late outcomes of valve repair versus replacement in isolated and concomitant tricuspid valve surgery: a nationwide cohort study. J Am Heart Assoc. 2020;9(8):e015637. doi.org/10.1161/JAHA.119.015637.
    10. Moraca RJ, Moon MR, Lawton JS, et al. Outcomes of tricuspid valve repair and replacement: a propensity analysis. Ann Thorac Surg. 2009;87(1):83–8; discussion 88¬–9. doi.org/10.1016/j.athoracsur.2008.10.003.

    © Abbott 2023. All rights reserved. 9-EH-5-14379-01 07-2023

    You are about to leave my-connext.com

    You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

    The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

    OK Decline